Close

Receptos (RCPT) Announces Completion of RADIANCE Phase 3 Enrollment

April 1, 2015 8:14 AM EDT Send to a Friend
Receptos (NASDAQ: RCPT) announced that the Company has completed enrollment in the RADIANCE Phase 3 trial of ozanimod (formerly RPC1063) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login